Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 11,388 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $13.02, for a total transaction of $148,271.76. Following the completion of the transaction, the chief financial officer owned 121,510 shares in the company, valued at $1,582,060.20. The trade was a 8.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Kory James Wentworth also recently made the following trade(s):

• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.00, for a total transaction of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total transaction of $97,853.00.

Entrada Therapeutics Price Performance

Shares of NASDAQ:TRDA traded up $0.30 during midday trading on Wednesday, hitting $13.50. The company had a trading volume of 210,880 shares, compared to its average volume of 236,376. The company has a market cap of $516.78 million, a price-to-earnings ratio of -3.90 and a beta of -0.12. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $13.66. The company has a fifty day moving average of $11.16 and a two-hundred day moving average of $8.83.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Research analysts expect that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Institutional Trading of Entrada Therapeutics

Several institutional investors have recently made changes to their positions in TRDA. Los Angeles Capital Management LLC raised its stake in Entrada Therapeutics by 60.6% during the 2nd quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock valued at $300,000 after purchasing an additional 16,840 shares during the period. Geode Capital Management LLC boosted its stake in Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after purchasing an additional 42,479 shares during the period. Intech Investment Management LLC grew its holdings in Entrada Therapeutics by 15.7% during the 2nd quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock valued at $119,000 after buying an additional 2,397 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Entrada Therapeutics during the 2nd quarter valued at approximately $166,000. Finally, Rhumbline Advisers raised its position in shares of Entrada Therapeutics by 8.3% during the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock valued at $263,000 after buying an additional 2,982 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on TRDA shares. Oppenheimer began coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.